Acurx announces publication of positive phase 2a clinical trial results of ibezapolstat for cdi in clinical infectious diseases

Staten island, n.y., feb. 7, 2022 /prnewswire/ --  publication of study presents: clinical results of 10 of 10 patients (100%) enrolled met the study's primary and secondary efficacy endpoints of clinical cure at end of treatment and sustained clinical cure of no recurrence of cdi at the 28-day follow-up visit pk data showing low plasma and high fecal concentrations of ibezapolstat favorable microbiome changes included regrowth of actinobacteria and firmicutes phylum species while on treatment potential beneficial effects on bile acid metabolism while on treatment currently enrolling ph2b trial in 12 u.s. sites will compare efficacy of ibezapolstat to vancomycin ibezapolstat is fda qidp and fast track designated for priority review acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that results of its positive phase 2a clinical trial have been published in clinical infectious diseases, the official publication of the infectious disease society of america https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac096/6522822?login=true.
ACXP Ratings Summary
ACXP Quant Ranking